Announcement

Collapse
No announcement yet.

US FluView - Weekly Surveillance Flu report 2021/2022 season - for trend analysis

Collapse
X
 
  • Filter
  • Time
  • Show
Clear All
new posts

  • #61
    Weekly U.S. Influenza Surveillance Report


    Updated August 19, 2022

    2021-2022 Influenza Season for Week 32, ending August 13, 2022

    All data are preliminary and may change as more reports are received.

    A description of the CDC influenza surveillance system, including methodology and detailed descriptions of each data component is available on the surveillance methods page.

    Additional information on the current and previous influenza seasons for each surveillance component are available on FluView Interactive.
    U.S. Virologic Surveillance

    Clinical Laboratories


    The results of tests performed by clinical laboratories nationwide are summarized below. Data from clinical laboratories (the percentage of specimens tested that are positive for influenza) are used to monitor whether influenza activity is increasing or decreasing.

    No. of specimens tested 41,657 3,385,846
    No. of positive specimens (%) 165 (0.4%) 134,111 (4.0%)
    Positive specimens by type
    Influenza A 147 (89.1%) 131,975 (98.4%)
    Influenza B 18 (10.9%) 2,136 (1.6%)

    View Chart Data | View Full Screen Public Health Laboratories


    The results of tests performed by public health laboratories nationwide are summarized below. Data from public health laboratories are used to monitor the proportion of circulating viruses that belong to each influenza subtype/lineage. Data from public health laboratories are used to monitor the proportion of circulating viruses that belong to each influenza subtype/lineage. Viruses known to be associated with recent live attenuated influenza vaccine (LAIV) receipt or found upon further testing to be a vaccine virus are not included, as they are not circulating influenza viruses.
    No. of specimens tested 11,925 1,019,489
    No. of positive specimens 27 25,565
    Positive specimens by type/subtype
    Influenza A 25 (92.6%) 25,421 (99.4%)
    (H1N1)pdm09 0 26 (0.1%)
    H3N2 20 (100%) 20,130 (99.9%)
    H3N2v 0 4 (<0.1%)
    Subtyping not performed 5 5,261
    Influenza B 2 (7.4%) 144 (0.6%)
    Yamagata lineage 0 1 (2.4%)
    Victoria lineage 0 40 (97.6%)
    Lineage not performed 2 103



    View Chart Data | View Full Screen

    Additional virologic surveillance information for current and past seasons:
    Surveillance Methods | FluView Interactive: National, Regional, and State Data or Age Data
    Novel Influenza A Virus


    A human infection with a novel influenza A virus was reported by the Oregon Health Authority. The patient was infected with an influenza A(H1N2) variant (A(H1N2)v) virus. The patients is <18 years of age, was not hospitalized, and has recovered from their illness. An investigation by local public health officials did not identify contact with swine or agricultural fair attendance by the patient prior to illness onset. Additional investigation did not identify respiratory illness in any of the patient’s household contacts. No person-to-person spread of this virus has been confirmed to date associated with this case. This is the first patient infected with an H1N2v virus reported in the United States in 2022.

    A total of four human infections with a variant influenza A virus have been reported in the United States in 2022, including three H3N2v (West Virginia) and one H1N2v (Oregon).

    When an influenza virus that normally circulates in swine (but not people) is detected in a person, it is called a “variant influenza virus.” Most human infections with variant influenza viruses occur following close proximity to swine, but human-to-human transmission can occur. It is important to note that in most cases, variant influenza viruses have not shown the ability to spread easily and sustainably from person to person.

    Early identification and investigation of human infections with novel influenza A viruses are critical so that the risk of infection can be understood, and appropriate public health measures can be taken. Additional information on influenza in swine, variant influenza virus infection in humans, and guidance to interact safely with swine can be found at www.cdc.gov/flu/swineflu/index.htm. Additional information regarding human infections with novel influenza A viruses can be found at http://gis.cdc.gov/grasp/fluview/Novel_Influenza.html.
    Outpatient Respiratory Illness Surveillance


    The U.S. Outpatient Influenza-like Illness Surveillance Network (ILINet) monitors outpatient visits for influenza-like illness [ILI (fever plus cough or sore throat)], not laboratory-confirmed influenza, and will therefore capture respiratory illness visits due to infection with any pathogen that can present with similar symptoms, including influenza, SARS-CoV-2, and RSV. Due to the COVID-19 pandemic, health care-seeking behaviors have changed, and people may be accessing the health care system in alternative settings not captured as a part of ILINet or at a different point in their illness than they might have before the pandemic. Therefore, it is important to evaluate syndromic surveillance data, including that from ILINet, in the context of other sources of surveillance data to obtain a complete and accurate picture of influenza, SARS-CoV-2, and other respiratory virus activity. CDC is tracking the COVID-19 pandemic in a weekly publication called COVID Data Tracker Weekly Review. Information about other respiratory virus activity can be found on CDC’s National Respiratory and Enteric Virus Surveillance System (NREVSS) website.
    Outpatient Respiratory Illness Visits


    Nationwide during week 32, 1.4% of patient visits reported through ILINet were due to respiratory illness that included fever plus a cough or sore throat, also referred to as ILI. Multiple respiratory viruses are co-circulating, and the relative contribution of influenza virus infection to ILI varies by location.



    * Effective October 3, 2021 (week 40), the ILI definition (fever plus cough or sore throat) no longer includes “without a known cause other than influenza.”


    View Chart Data (current season only) | View Full ScreenOutpatient Respiratory Illness Visits by Age Group


    More than 70% of ILINet participants provide both the number of patient visits for respiratory illness and the total number of patient visits for the week broken out by age group. Data from this subset of providers are used to calculate the percentages of patient visits for respiratory illness by age group.

    During week 32, the percentage of visits for respiratory illness reported in ILINet was 5.9% among those 0-4 years, 2.0% among those 5-24 years, 1.1% among those 25-49 years, 0.8% among those 50-64 years, and 0.7% among those 65 years and older.



    * Effective October 3, 2021 (week 40), the ILI definition (fever plus cough or sore throat) no longer includes “without a known cause other than influenza.”

    View Chart Data | View Full Screen
    Outpatient Respiratory Illness Activity Map


    Data collected in ILINet are used to produce a measure of ILI activity* by state/jurisdiction and Core Based Statistical Areas (CBSA).
    Week 32
    (Week ending
    Aug. 13, 2022)
    Week 31
    (Week ending
    Aug. 6, 2022)
    Week 32
    (Week ending
    Aug. 13, 2022)
    Week 31
    (Week ending
    Aug. 6, 2022)
    Very High 0 0 1 1
    High 0 0 5 4
    Moderate 0 1 14 10
    Low 3 1 35 54
    Minimal 51 53 581 588
    Insufficient Data 1 0 293 272



    *Data collected in ILINet may disproportionally represent certain populations within a jurisdiction or CBSA, and therefore, may not accurately depict the full picture of influenza activity for the entire jurisdiction or CBSA. Differences in the data presented here by CDC and independently by some health departments likely represent differing levels of data completeness with data presented by the health department likely being the more complete.

    Additional information about medically attended visits for ILI for current and past seasons:
    Surveillance Methods | FluView Interactive: National, Regional, and State Data or ILI Activity Map
    Long-term Care Facility (LTCF) Surveillance


    LTCFs (e.g., nursing homes/skilled nursing, long-term care for the developmentally disabled, and assisted living facilities) from all 50 states and U.S. territories report data on influenza virus infections among residents through the National Healthcare Safety Network (NHSN) Long-term Care Facility Component. During week 32, 39 (0.3%) of 14,576 reporting LTCFs reported at least one influenza positive test among their residents.



    View Chart Data | View Full Screen

    Additional information about long-term care facility surveillance:
    Surveillance Methods | Additional Data
    Hospitalization Surveillance

    FluSurv-NET


    The Influenza Hospitalization Surveillance Network (FluSurv-NET) conducts population-based surveillance for laboratory-confirmed influenza-related hospitalizations in select counties in 14 states and represents approximately 9% of the U.S. population. FluSurv-NET hospitalization data are preliminary. Patients admitted for laboratory-confirmed influenza-related hospitalization after June 11, 2022, will not be included in FluSurv-NET for the 2021-2022 season. Data on patients admitted through June 11, 2022, will continue to be updated as additional information is received.

    Additional FluSurv-NET hospitalization surveillance information for current and past seasons and additional age groups:
    Surveillance Methods |FluView Interactive: Rates by Age, Sex, and Race/Ethnicity or Data on Patient Characteristics
    HHS Protect Hospitalization Surveillance


    Hospitals report to HHS Protect the number of patients admitted with laboratory-confirmed influenza. During week 32, 457 patients with laboratory-confirmed influenza were admitted to the hospital.



    View Chart Data | View Full Screen

    Additional HHS Protect hospitalization surveillance information:
    Surveillance Methods | Additional Data
    Mortality Surveillance

    National Center for Health Statistics (NCHS) Mortality Surveillance


    Based on NCHS mortality surveillance data available on August 18, 2022, 9.9% of the deaths that occurred during the week ending August 13, 2022 (week 32), were due to pneumonia, influenza, and/or COVID-19 (PIC). This percentage is above the epidemic threshold of 5.5% for this week. Among the 2,165 PIC deaths reported for this week, 1,192 had COVID-19 listed as an underlying or contributing cause of death on the death certificate, and six listed influenza, indicating that current PIC mortality is due primarily to COVID-19 and not influenza. The data presented are preliminary and may change as more data are received and processed.



    View Chart Data | View Full Screen

    Additional pneumonia, influenza and COVID-19 mortality surveillance information for current and past seasons:
    Surveillance Methods | FluView Interactive
    Influenza-Associated Pediatric Mortality


    No influenza-associated pediatric death occurring during the 2021-2022 season were reported to CDC during week 32.

    A total of 33 influenza-associated pediatric deaths occurring during the 2021-2022 season have been reported to CDC.


    View Full Screen

    Additional pediatric mortality surveillance information for current and past seasons:
    Surveillance Methods | FluView Interactive


    Additional National and International Influenza Surveillance Information


    FluView Interactive: FluView includes enhanced web-based interactive applications that can provide dynamic visuals of the influenza data collected and analyzed by CDC. These FluView Interactive applications allow people to create customized, visual interpretations of influenza data, as well as make comparisons across flu seasons, regions, age groups and a variety of other demographics.

    National Institute for Occupational Safety and Health: Monthly surveillance data on the prevalence of health-related workplace absenteeism among full-time workers in the United States are available from NIOSH.

    U.S. State and local influenza surveillance: Select a jurisdiction below to access the latest local influenza information. World Health Organization:
    Additional influenza surveillance information from participating WHO member nations is available through
    FluNet and the Global Epidemiology Reports.

    WHO Collaborating Centers for Influenza:
    Australia, China, Japan, the United Kingdom, and the United States (CDC in Atlanta, Georgia)

    Europe:
    The most up-to-date influenza information from Europe is available from WHO/Europe and the European Centre for Disease Prevention and Control.

    Public Health Agency of Canada:
    The most up-to-date influenza information from Canada is available in Canada’s weekly FluWatch report.

    Public Health England:
    The most up-to-date influenza information from the United Kingdom is available from Public Health England.

    Any links provided to non-Federal organizations are provided solely as a service to our users. These links do not constitute an endorsement of these organizations or their programs by CDC or the Federal Government, and none should be inferred. CDC is not responsible for the content of the individual organization web pages found at these links.

    A description of the CDC influenza surveillance system, including methodology and detailed descriptions of each data component is available on the surveillance methods page.

    Learn more about the weekly influenza surveillance report (FluView) prepared by the Influenza Division.

    Comment


    • #62
      Weekly U.S. Influenza Surveillance Report


      Updated August 26, 2022

      2021-2022 Influenza Season for Week 33, ending August 20, 2022

      All data are preliminary and may change as more reports are received.

      A description of the CDC influenza surveillance system, including methodology and detailed descriptions of each data component is available on the surveillance methods page.

      Additional information on the current and previous influenza seasons for each surveillance component are available on FluView Interactive.
      U.S. Virologic Surveillance

      Clinical Laboratories


      The results of tests performed by clinical laboratories nationwide are summarized below. Data from clinical laboratories (the percentage of specimens tested that are positive for influenza) are used to monitor whether influenza activity is increasing or decreasing.

      No. of specimens tested 32,491 3,431,123
      No. of positive specimens (%) 159 (0.5%) 134,375 (3.9%)
      Positive specimens by type
      Influenza A 136 (85.5%) 132,205 (98.4%)
      Influenza B 23 (14.5%) 2,170 (1.6%)

      View Chart Data | View Full Screen Public Health Laboratories


      The results of tests performed by public health laboratories nationwide are summarized below. Data from public health laboratories are used to monitor the proportion of circulating viruses that belong to each influenza subtype/lineage. Data from public health laboratories are used to monitor the proportion of circulating viruses that belong to each influenza subtype/lineage. Viruses known to be associated with recent live attenuated influenza vaccine (LAIV) receipt or found upon further testing to be a vaccine virus are not included, as they are not circulating influenza viruses.
      No. of specimens tested 11,062 1,059,682
      No. of positive specimens 39 25,703
      Positive specimens by type/subtype
      Influenza A 37 (94.9%) 25,557 (99.4%)
      (H1N1)pdm09 1 (3.4%) 28 (0.1%)
      H3N2 28 (96.6%) 20,237 (99.9%)
      H3N2v 0 4 (<0.1%)
      Subtyping not performed 8 5,288
      Influenza B 2 (5.1%) 146 (0.6%)
      Yamagata lineage 0 1 (2.4%)
      Victoria lineage 1 (100%) 41 (97.6%)
      Lineage not performed 1 104



      View Chart Data | View Full Screen

      Additional virologic surveillance information for current and past seasons:
      Surveillance Methods | FluView Interactive: National, Regional, and State Data or Age Data
      Novel Influenza A Virus


      A human infection with a novel influenza A virus was reported by the Ohio Department of Health. The patient was infected with a swine-origin influenza A(H1N2) variant (A(H1N2)v) virus. The patient is <18 years of age, was not hospitalized, and has recovered from their illness. An investigation by local public health officials found that the patient had attended an agricultural fair on the day of their illness onset. Additional investigation did not identify respiratory illness in any of the patient’s household contacts. No person-to-person transmission of A(H1N2)v virus associated with this patient has been identified. This is the second patient infected with an H1N2v virus reported in the United States in 2022.

      A total of five human infections with variant influenza A viruses have been reported in the United States in 2022, including three H3N2v (West Virginia) and two H1N2v (Ohio, Oregon) viruses. When an influenza virus that normally circulates in swine (but not people) is detected in a person, it is called a “variant” influenza virus. Most human infections with variant influenza viruses occur following exposure to swine, but human-to-human transmission can occur. It is important to note that in most cases, variant influenza viruses have not shown the ability to spread easily and sustainably from person to person.

      Early identification and investigation of human infections with novel influenza A viruses are critical so that the risk of infection can be understood, and appropriate public health measures can be taken. Additional information on influenza in swine, variant influenza virus infection in humans, and guidance to interact safely with swine can be found at www.cdc.gov/flu/swineflu/index.htm.

      Additional information regarding human infections with novel influenza A viruses can be found at http://gis.cdc.gov/grasp/fluview/Novel_Influenza.html.
      Outpatient Respiratory Illness Surveillance


      The U.S. Outpatient Influenza-like Illness Surveillance Network (ILINet) monitors outpatient visits for influenza-like illness [ILI (fever plus cough or sore throat)], not laboratory-confirmed influenza, and will therefore capture respiratory illness visits due to infection with any pathogen that can present with similar symptoms, including influenza, SARS-CoV-2, and RSV. Due to the COVID-19 pandemic, health care-seeking behaviors have changed, and people may be accessing the health care system in alternative settings not captured as a part of ILINet or at a different point in their illness than they might have before the pandemic. Therefore, it is important to evaluate syndromic surveillance data, including that from ILINet, in the context of other sources of surveillance data to obtain a complete and accurate picture of influenza, SARS-CoV-2, and other respiratory virus activity. CDC is tracking the COVID-19 pandemic in a weekly publication called COVID Data Tracker Weekly Review. Information about other respiratory virus activity can be found on CDC’s National Respiratory and Enteric Virus Surveillance System (NREVSS) website.
      Outpatient Respiratory Illness Visits


      Nationwide during week 33, 1.5% of patient visits reported through ILINet were due to respiratory illness that included fever plus a cough or sore throat, also referred to as ILI. Multiple respiratory viruses are co-circulating, and the relative contribution of influenza virus infection to ILI varies by location.



      * Effective October 3, 2021 (week 40), the ILI definition (fever plus cough or sore throat) no longer includes “without a known cause other than influenza.”


      View Chart Data (current season only) | View Full ScreenOutpatient Respiratory Illness Visits by Age Group


      More than 70% of ILINet participants provide both the number of patient visits for respiratory illness and the total number of patient visits for the week broken out by age group. Data from this subset of providers are used to calculate the percentages of patient visits for respiratory illness by age group.

      During week 33, the percentage of visits for respiratory illness reported in ILINet was 6.3% among those 0-4 years, 2.4% among those 5-24 years, 1.0% among those 25-49 years, 0.8% among those 50-64 years, and 0.6% among those 65 years and older.



      * Effective October 3, 2021 (week 40), the ILI definition (fever plus cough or sore throat) no longer includes “without a known cause other than influenza.”

      View Chart Data | View Full Screen
      Outpatient Respiratory Illness Activity Map


      Data collected in ILINet are used to produce a measure of ILI activity* by state/jurisdiction and Core Based Statistical Areas (CBSA).
      Week 33
      (Week ending
      Aug. 20, 2022)
      Week 32
      (Week ending
      Aug. 13, 2022)
      Week 33
      (Week ending
      Aug. 20, 2022)
      Week 32
      (Week ending
      Aug. 13, 2022)
      Very High 0 0 1 2
      High 1 0 6 5
      Moderate 2 0 20 15
      Low 1 3 56 36
      Minimal 51 52 568 587
      Insufficient Data 0 0 278 284



      *Data collected in ILINet may disproportionally represent certain populations within a jurisdiction or CBSA, and therefore, may not accurately depict the full picture of influenza activity for the entire jurisdiction or CBSA. Differences in the data presented here by CDC and independently by some health departments likely represent differing levels of data completeness with data presented by the health department likely being the more complete.

      Additional information about medically attended visits for ILI for current and past seasons:
      Surveillance Methods | FluView Interactive: National, Regional, and State Data or ILI Activity Map
      Long-term Care Facility (LTCF) Surveillance


      LTCFs (e.g., nursing homes/skilled nursing, long-term care for the developmentally disabled, and assisted living facilities) from all 50 states and U.S. territories report data on influenza virus infections among residents through the National Healthcare Safety Network (NHSN) Long-term Care Facility Component. During week 33, 31 (0.2%) of 14,575 reporting LTCFs reported at least one influenza positive test among their residents.



      View Chart Data | View Full Screen

      Additional information about long-term care facility surveillance:
      Surveillance Methods | Additional Data
      Hospitalization Surveillance

      FluSurv-NET


      The Influenza Hospitalization Surveillance Network (FluSurv-NET) conducts population-based surveillance for laboratory-confirmed influenza-related hospitalizations in select counties in 14 states and represents approximately 9% of the U.S. population. FluSurv-NET hospitalization data are preliminary. Patients admitted for laboratory-confirmed influenza-related hospitalization after June 11, 2022, will not be included in FluSurv-NET for the 2021-2022 season. Data on patients admitted through June 11, 2022, will continue to be updated as additional information is received.

      Additional FluSurv-NET hospitalization surveillance information for current and past seasons and additional age groups:
      Surveillance Methods |FluView Interactive: Rates by Age, Sex, and Race/Ethnicity or Data on Patient Characteristics
      HHS Protect Hospitalization Surveillance


      Hospitals report to HHS Protect the number of patients admitted with laboratory-confirmed influenza. During week 33, 477 patients with laboratory-confirmed influenza were admitted to the hospital.



      View Chart Data | View Full Screen

      Additional HHS Protect hospitalization surveillance information:
      Surveillance Methods | Additional Data
      Mortality Surveillance

      National Center for Health Statistics (NCHS) Mortality Surveillance


      Based on NCHS mortality surveillance data available on August 25, 2022, 10.0% of the deaths that occurred during the week ending August 20, 2022 (week 33), were due to pneumonia, influenza, and/or COVID-19 (PIC). This percentage is above the epidemic threshold of 5.5% for this week. Among the 2,320 PIC deaths reported for this week, 1,268 had COVID-19 listed as an underlying or contributing cause of death on the death certificate, and seven listed influenza, indicating that current PIC mortality is due primarily to COVID-19 and not influenza. The data presented are preliminary and may change as more data are received and processed.



      View Chart Data | View Full Screen

      Additional pneumonia, influenza and COVID-19 mortality surveillance information for current and past seasons:
      Surveillance Methods | FluView Interactive
      Influenza-Associated Pediatric Mortality


      No influenza-associated pediatric death occurring during the 2021-2022 season were reported to CDC during week 33.

      A total of 33 influenza-associated pediatric deaths occurring during the 2021-2022 season have been reported to CDC.


      View Full Screen

      Additional pediatric mortality surveillance information for current and past seasons:
      Surveillance Methods | FluView Interactive


      Additional National and International Influenza Surveillance Information


      FluView Interactive: FluView includes enhanced web-based interactive applications that can provide dynamic visuals of the influenza data collected and analyzed by CDC. These FluView Interactive applications allow people to create customized, visual interpretations of influenza data, as well as make comparisons across flu seasons, regions, age groups and a variety of other demographics.

      National Institute for Occupational Safety and Health: Monthly surveillance data on the prevalence of health-related workplace absenteeism among full-time workers in the United States are available from NIOSH.

      U.S. State and local influenza surveillance: Select a jurisdiction below to access the latest local influenza information. World Health Organization:
      Additional influenza surveillance information from participating WHO member nations is available through
      FluNet and the Global Epidemiology Reports.

      WHO Collaborating Centers for Influenza:
      Australia, China, Japan, the United Kingdom, and the United States (CDC in Atlanta, Georgia)

      Europe:
      The most up-to-date influenza information from Europe is available from WHO/Europe and the European Centre for Disease Prevention and Control.

      Public Health Agency of Canada:
      The most up-to-date influenza information from Canada is available in Canada’s weekly FluWatch report.

      Public Health England:
      The most up-to-date influenza information from the United Kingdom is available from Public Health England.

      Any links provided to non-Federal organizations are provided solely as a service to our users. These links do not constitute an endorsement of these organizations or their programs by CDC or the Federal Government, and none should be inferred. CDC is not responsible for the content of the individual organization web pages found at these links.

      A description of the CDC influenza surveillance system, including methodology and detailed descriptions of each data component is available on the surveillance methods page.

      Learn more about the weekly influenza surveillance report (FluView) prepared by the Influenza Division.

      Comment


      • #63
        Weekly U.S. Influenza Surveillance Report


        Updated September 2, 2022

        2021-2022 Influenza Season for Week 34, ending August 27, 2022

        All data are preliminary and may change as more reports are received.

        A description of the CDC influenza surveillance system, including methodology and detailed descriptions of each data component is available on the surveillance methods page.

        Additional information on the current and previous influenza seasons for each surveillance component are available on FluView Interactive.
        U.S. Virologic Surveillance

        Clinical Laboratories


        The results of tests performed by clinical laboratories nationwide are summarized below. Data from clinical laboratories (the percentage of specimens tested that are positive for influenza) are used to monitor whether influenza activity is increasing or decreasing.

        No. of specimens tested 41,365 3,491,587
        No. of positive specimens (%) 209 (0.5%) 134,683 (3.9%)
        Positive specimens by type
        Influenza A 182 (87.1%) 132,473 (98.4%)
        Influenza B 27 (12.9%) 2,210 (1.6%)

        View Chart Data | View Full Screen Public Health Laboratories


        The results of tests performed by public health laboratories nationwide are summarized below. Data from public health laboratories are used to monitor the proportion of circulating viruses that belong to each influenza subtype/lineage. Data from public health laboratories are used to monitor the proportion of circulating viruses that belong to each influenza subtype/lineage. Viruses known to be associated with recent live attenuated influenza vaccine (LAIV) receipt or found upon further testing to be a vaccine virus are not included, as they are not circulating influenza viruses.
        No. of specimens tested 10,805 1,071,312
        No. of positive specimens 40 25,775
        Positive specimens by type/subtype
        Influenza A 39 (97.5%) 25,628 (99.4%)
        (H1N1)pdm09 5 (17.9%) 39 (0.2%)
        H3N2 23 (82.1%) 20,307 (99.8%)
        H3N2v 0 4 (<0.1%)
        Subtyping not performed 11 5,278
        Influenza B 1 (2.5%) 147 (0.6%)
        Yamagata lineage 0 1 (2.3%)
        Victoria lineage 1 (100%) 42 (97.7%)
        Lineage not performed 0 104



        View Chart Data | View Full Screen

        Additional virologic surveillance information for current and past seasons:
        Surveillance Methods | FluView Interactive: National, Regional, and State Data or Age Data
        Outpatient Respiratory Illness Surveillance


        The U.S. Outpatient Influenza-like Illness Surveillance Network (ILINet) monitors outpatient visits for influenza-like illness [ILI (fever plus cough or sore throat)], not laboratory-confirmed influenza, and will therefore capture respiratory illness visits due to infection with any pathogen that can present with similar symptoms, including influenza, SARS-CoV-2, and RSV. Due to the COVID-19 pandemic, health care-seeking behaviors have changed, and people may be accessing the health care system in alternative settings not captured as a part of ILINet or at a different point in their illness than they might have before the pandemic. Therefore, it is important to evaluate syndromic surveillance data, including that from ILINet, in the context of other sources of surveillance data to obtain a complete and accurate picture of influenza, SARS-CoV-2, and other respiratory virus activity. CDC is tracking the COVID-19 pandemic in a weekly publication called COVID Data Tracker Weekly Review. Information about other respiratory virus activity can be found on CDC’s National Respiratory and Enteric Virus Surveillance System (NREVSS) website.
        Outpatient Respiratory Illness Visits


        Nationwide during week 34, 1.8% of patient visits reported through ILINet were due to respiratory illness that included fever plus a cough or sore throat, also referred to as ILI. Multiple respiratory viruses are co-circulating, and the relative contribution of influenza virus infection to ILI varies by location.



        * Effective October 3, 2021 (week 40), the ILI definition (fever plus cough or sore throat) no longer includes “without a known cause other than influenza.”


        View Chart Data (current season only) | View Full ScreenOutpatient Respiratory Illness Visits by Age Group


        More than 70% of ILINet participants provide both the number of patient visits for respiratory illness and the total number of patient visits for the week broken out by age group. Data from this subset of providers are used to calculate the percentages of patient visits for respiratory illness by age group.

        During week 34, the percentage of visits for respiratory illness reported in ILINet was 7.0% among those 0-4 years, 2.9% among those 5-24 years, 1.1% among those 25-49 years, 0.7% among those 50-64 years, and 0.6% among those 65 years and older.



        * Effective October 3, 2021 (week 40), the ILI definition (fever plus cough or sore throat) no longer includes “without a known cause other than influenza.”

        View Chart Data | View Full Screen
        Outpatient Respiratory Illness Activity Map


        Data collected in ILINet are used to produce a measure of ILI activity* by state/jurisdiction and Core Based Statistical Areas (CBSA).
        Week 34
        (Week ending
        Aug. 27, 2022)
        Week 33
        (Week ending
        Aug. 20, 2022)
        Week 34
        (Week ending
        Aug. 27, 2022)
        Week 33
        (Week ending
        Aug. 20, 2022)
        Very High 0 0 3 2
        High 1 1 10 6
        Moderate 3 1 18 21
        Low 2 2 74 56
        Minimal 47 51 537 574
        Insufficient Data 2 0 287 270



        *Data collected in ILINet may disproportionally represent certain populations within a jurisdiction or CBSA, and therefore, may not accurately depict the full picture of influenza activity for the entire jurisdiction or CBSA. Differences in the data presented here by CDC and independently by some health departments likely represent differing levels of data completeness with data presented by the health department likely being the more complete.

        Additional information about medically attended visits for ILI for current and past seasons:
        Surveillance Methods | FluView Interactive: National, Regional, and State Data or ILI Activity Map
        Long-term Care Facility (LTCF) Surveillance


        LTCFs (e.g., nursing homes/skilled nursing, long-term care for the developmentally disabled, and assisted living facilities) from all 50 states and U.S. territories report data on influenza virus infections among residents through the National Healthcare Safety Network (NHSN) Long-term Care Facility Component. During week 34, 28 (0.2%) of 14,510 reporting LTCFs reported at least one influenza positive test among their residents.



        View Chart Data | View Full Screen

        Additional information about long-term care facility surveillance:
        Surveillance Methods | Additional Data
        Hospitalization Surveillance

        FluSurv-NET


        The Influenza Hospitalization Surveillance Network (FluSurv-NET) conducts population-based surveillance for laboratory-confirmed influenza-related hospitalizations in select counties in 14 states and represents approximately 9% of the U.S. population. FluSurv-NET hospitalization data are preliminary. Patients admitted for laboratory-confirmed influenza-related hospitalization after June 11, 2022, will not be included in FluSurv-NET for the 2021-2022 season. Data on patients admitted through June 11, 2022, will continue to be updated as additional information is received.

        Additional FluSurv-NET hospitalization surveillance information for current and past seasons and additional age groups:
        Surveillance Methods |FluView Interactive: Rates by Age, Sex, and Race/Ethnicity or Data on Patient Characteristics
        HHS Protect Hospitalization Surveillance


        Hospitals report to HHS Protect the number of patients admitted with laboratory-confirmed influenza. During week 34, 486 patients with laboratory-confirmed influenza were admitted to the hospital.



        View Chart Data | View Full Screen

        Additional HHS Protect hospitalization surveillance information:
        Surveillance Methods | Additional Data
        Mortality Surveillance

        National Center for Health Statistics (NCHS) Mortality Surveillance


        Based on NCHS mortality surveillance data available on September 1, 2022, 9.2% of the deaths that occurred during the week ending August 27, 2022 (week 34), were due to pneumonia, influenza, and/or COVID-19 (PIC). This percentage is above the epidemic threshold of 5.5% for this week. Among the 2,117 PIC deaths reported for this week, 1,120 had COVID-19 listed as an underlying or contributing cause of death on the death certificate, and eight listed influenza, indicating that current PIC mortality is due primarily to COVID-19 and not influenza. The data presented are preliminary and may change as more data are received and processed.



        View Chart Data | View Full Screen

        Additional pneumonia, influenza and COVID-19 mortality surveillance information for current and past seasons:
        Surveillance Methods | FluView Interactive
        Influenza-Associated Pediatric Mortality


        One influenza-associated pediatric death occurring during the 2021-2022 season was reported to CDC during week 34. The death was associated with an influenza A virus for which no subtyping was performed and occurred during week 29 (the week ending July 23, 2022).

        A total of 34 influenza-associated pediatric deaths occurring during the 2021-2022 season have been reported to CDC.


        View Full Screen

        Additional pediatric mortality surveillance information for current and past seasons:
        Surveillance Methods | FluView Interactive


        Additional National and International Influenza Surveillance Information


        FluView Interactive: FluView includes enhanced web-based interactive applications that can provide dynamic visuals of the influenza data collected and analyzed by CDC. These FluView Interactive applications allow people to create customized, visual interpretations of influenza data, as well as make comparisons across flu seasons, regions, age groups and a variety of other demographics.

        National Institute for Occupational Safety and Health: Monthly surveillance data on the prevalence of health-related workplace absenteeism among full-time workers in the United States are available from NIOSH.

        U.S. State and local influenza surveillance: Select a jurisdiction below to access the latest local influenza information. World Health Organization:
        Additional influenza surveillance information from participating WHO member nations is available through
        FluNet and the Global Epidemiology Reports.

        WHO Collaborating Centers for Influenza:
        Australia, China, Japan, the United Kingdom, and the United States (CDC in Atlanta, Georgia)

        Europe:
        The most up-to-date influenza information from Europe is available from WHO/Europe and the European Centre for Disease Prevention and Control.

        Public Health Agency of Canada:
        The most up-to-date influenza information from Canada is available in Canada’s weekly FluWatch report.

        Public Health England:
        The most up-to-date influenza information from the United Kingdom is available from Public Health England.

        Any links provided to non-Federal organizations are provided solely as a service to our users. These links do not constitute an endorsement of these organizations or their programs by CDC or the Federal Government, and none should be inferred. CDC is not responsible for the content of the individual organization web pages found at these links.

        A description of the CDC influenza surveillance system, including methodology and detailed descriptions of each data component is available on the surveillance methods page.

        Learn more about the weekly influenza surveillance report (FluView) prepared by the Influenza Division.

        Comment


        • #64
          Weekly U.S. Influenza Surveillance Report


          Updated September 9, 2022

          2021-2022 Influenza Season for Week 35, ending September 3, 2022

          All data are preliminary and may change as more reports are received.

          A description of the CDC influenza surveillance system, including methodology and detailed descriptions of each data component is available on the surveillance methods page.

          Additional information on the current and previous influenza seasons for each surveillance component are available on FluView Interactive.
          U.S. Virologic Surveillance

          Clinical Laboratories


          The results of tests performed by clinical laboratories nationwide are summarized below. Data from clinical laboratories (the percentage of specimens tested that are positive for influenza) are used to monitor whether influenza activity is increasing or decreasing.

          No. of specimens tested 42,261 3,547,791
          No. of positive specimens (%) 247 (0.6%) 135,046 (3.8%)
          Positive specimens by type
          Influenza A 228 (92.3%) 132,809 (98.3%)
          Influenza B 19 (7.7%) 2,237 (1.7%)

          View Chart Data | View Full Screen Public Health Laboratories


          The results of tests performed by public health laboratories nationwide are summarized below. Data from public health laboratories are used to monitor the proportion of circulating viruses that belong to each influenza subtype/lineage. Data from public health laboratories are used to monitor the proportion of circulating viruses that belong to each influenza subtype/lineage. Viruses known to be associated with recent live attenuated influenza vaccine (LAIV) receipt or found upon further testing to be a vaccine virus are not included, as they are not circulating influenza viruses.
          No. of specimens tested 10,106 1,082,187
          No. of positive specimens 18 25,893
          Positive specimens by type/subtype
          Influenza A 15 (83.3%) 25,743 (99.4%)
          (H1N1)pdm09 4 (50.0%) 46 (0.2%)
          H3N2 4 (50.0%) 20,385 (99.8%)
          H3N2v 0 4 (<0.1%)
          Subtyping not performed 7 5,308
          Influenza B 3 (16.7%) 150 (0.6%)
          Yamagata lineage 0 1 (2.3%)
          Victoria lineage 0 42 (97.7%)
          Lineage not performed 3 107



          View Chart Data | View Full Screen

          Additional virologic surveillance information for current and past seasons:
          Surveillance Methods | FluView Interactive: National, Regional, and State Data or Age Data
          Outpatient Respiratory Illness Surveillance


          The U.S. Outpatient Influenza-like Illness Surveillance Network (ILINet) monitors outpatient visits for influenza-like illness [ILI (fever plus cough or sore throat)], not laboratory-confirmed influenza, and will therefore capture respiratory illness visits due to infection with any pathogen that can present with similar symptoms, including influenza, SARS-CoV-2, and RSV. Due to the COVID-19 pandemic, health care-seeking behaviors have changed, and people may be accessing the health care system in alternative settings not captured as a part of ILINet or at a different point in their illness than they might have before the pandemic. Therefore, it is important to evaluate syndromic surveillance data, including that from ILINet, in the context of other sources of surveillance data to obtain a complete and accurate picture of influenza, SARS-CoV-2, and other respiratory virus activity. CDC is tracking the COVID-19 pandemic in a weekly publication called COVID Data Tracker Weekly Review. Information about other respiratory virus activity can be found on CDC’s National Respiratory and Enteric Virus Surveillance System (NREVSS) website.
          Outpatient Respiratory Illness Visits


          Nationwide during week 35, 1.9% of patient visits reported through ILINet were due to respiratory illness that included fever plus a cough or sore throat, also referred to as ILI. Multiple respiratory viruses are co-circulating, and the relative contribution of influenza virus infection to ILI varies by location.



          * Effective October 3, 2021 (week 40), the ILI definition (fever plus cough or sore throat) no longer includes “without a known cause other than influenza.”


          View Chart Data (current season only) | View Full ScreenOutpatient Respiratory Illness Visits by Age Group


          More than 70% of ILINet participants provide both the number of patient visits for respiratory illness and the total number of patient visits for the week broken out by age group. Data from this subset of providers are used to calculate the percentages of patient visits for respiratory illness by age group.

          During week 35, the percentage of visits for respiratory illness reported in ILINet was 7.2% among those 0-4 years, 3.0% among those 5-24 years, 1.1% among those 25-49 years, 0.7% among those 50-64 years, and 0.6% among those 65 years and older.



          * Effective October 3, 2021 (week 40), the ILI definition (fever plus cough or sore throat) no longer includes “without a known cause other than influenza.”

          View Chart Data | View Full Screen
          Outpatient Respiratory Illness Activity Map


          Data collected in ILINet are used to produce a measure of ILI activity* by state/jurisdiction and Core Based Statistical Areas (CBSA).
          Week 35
          (Week ending
          Sep. 3, 2022)
          Week 34
          (Week ending
          Aug. 27, 2022)
          Week 35
          (Week ending
          Sep. 3, 2022)
          Week 34
          (Week ending
          Aug. 27, 2022)
          Very High 0 0 3 4
          High 3 1 8 10
          Moderate 2 3 25 20
          Low 2 2 60 74
          Minimal 45 48 524 542
          Insufficient Data 3 1 309 279



          *Data collected in ILINet may disproportionally represent certain populations within a jurisdiction or CBSA, and therefore, may not accurately depict the full picture of influenza activity for the entire jurisdiction or CBSA. Differences in the data presented here by CDC and independently by some health departments likely represent differing levels of data completeness with data presented by the health department likely being the more complete.

          Additional information about medically attended visits for ILI for current and past seasons:
          Surveillance Methods | FluView Interactive: National, Regional, and State Data or ILI Activity Map
          Long-term Care Facility (LTCF) Surveillance


          LTCFs (e.g., nursing homes/skilled nursing, long-term care for the developmentally disabled, and assisted living facilities) from all 50 states and U.S. territories report data on influenza virus infections among residents through the National Healthcare Safety Network (NHSN) Long-term Care Facility Component. During week 35, 28 (0.2%) of 14,481 reporting LTCFs reported at least one influenza positive test among their residents.



          View Chart Data | View Full Screen

          Additional information about long-term care facility surveillance:
          Surveillance Methods | Additional Data
          Hospitalization Surveillance

          FluSurv-NET


          The Influenza Hospitalization Surveillance Network (FluSurv-NET) conducts population-based surveillance for laboratory-confirmed influenza-related hospitalizations in select counties in 14 states and represents approximately 9% of the U.S. population. FluSurv-NET hospitalization data are preliminary. Patients admitted for laboratory-confirmed influenza-related hospitalization after June 11, 2022, will not be included in FluSurv-NET for the 2021-2022 season. Data on patients admitted through June 11, 2022, will continue to be updated as additional information is received.

          Additional FluSurv-NET hospitalization surveillance information for current and past seasons and additional age groups:
          Surveillance Methods |FluView Interactive: Rates by Age, Sex, and Race/Ethnicity or Data on Patient Characteristics
          HHS Protect Hospitalization Surveillance


          Hospitals report to HHS Protect the number of patients admitted with laboratory-confirmed influenza. During week 35, 509 patients with laboratory-confirmed influenza were admitted to the hospital.



          View Chart Data | View Full Screen

          Additional HHS Protect hospitalization surveillance information:
          Surveillance Methods | Additional Data
          Mortality Surveillance

          National Center for Health Statistics (NCHS) Mortality Surveillance


          Based on NCHS mortality surveillance data available on September 8, 2022, 9.6% of the deaths that occurred during the week ending September 3, 2022 (week 35), were due to pneumonia, influenza, and/or COVID-19 (PIC). This percentage is above the epidemic threshold of 5.5% for this week. Among the 1,769 PIC deaths reported for this week, 963 had COVID-19 listed as an underlying or contributing cause of death on the death certificate, and seven listed influenza, indicating that current PIC mortality is due primarily to COVID-19 and not influenza. The data presented are preliminary and may change as more data are received and processed.



          View Chart Data | View Full Screen

          Additional pneumonia, influenza and COVID-19 mortality surveillance information for current and past seasons:
          Surveillance Methods | FluView Interactive
          Influenza-Associated Pediatric Mortality


          No influenza-associated pediatric deaths occurring during the 2021-2022 season were reported to CDC during week 35.

          A total of 34 influenza-associated pediatric deaths occurring during the 2021-2022 season have been reported to CDC.


          View Full Screen

          Additional pediatric mortality surveillance information for current and past seasons:
          Surveillance Methods | FluView Interactive


          Additional National and International Influenza Surveillance Information


          FluView Interactive: FluView includes enhanced web-based interactive applications that can provide dynamic visuals of the influenza data collected and analyzed by CDC. These FluView Interactive applications allow people to create customized, visual interpretations of influenza data, as well as make comparisons across flu seasons, regions, age groups and a variety of other demographics.

          National Institute for Occupational Safety and Health: Monthly surveillance data on the prevalence of health-related workplace absenteeism among full-time workers in the United States are available from NIOSH.

          U.S. State and local influenza surveillance: Select a jurisdiction below to access the latest local influenza information. World Health Organization:
          Additional influenza surveillance information from participating WHO member nations is available through
          FluNet and the Global Epidemiology Reports.

          WHO Collaborating Centers for Influenza:
          Australia, China, Japan, the United Kingdom, and the United States (CDC in Atlanta, Georgia)

          Europe:
          The most up-to-date influenza information from Europe is available from WHO/Europe and the European Centre for Disease Prevention and Control.

          Public Health Agency of Canada:
          The most up-to-date influenza information from Canada is available in Canada’s weekly FluWatch report.

          Public Health England:
          The most up-to-date influenza information from the United Kingdom is available from Public Health England.

          Any links provided to non-Federal organizations are provided solely as a service to our users. These links do not constitute an endorsement of these organizations or their programs by CDC or the Federal Government, and none should be inferred. CDC is not responsible for the content of the individual organization web pages found at these links.

          A description of the CDC influenza surveillance system, including methodology and detailed descriptions of each data component is available on the surveillance methods page.

          Learn more about the weekly influenza surveillance report (FluView) prepared by the Influenza Division.

          Comment


          • #65
            Weekly U.S. Influenza Surveillance Report


            Updated September 16, 2022

            2021-2022 Influenza Season for Week 36, ending September 10, 2022

            All data are preliminary and may change as more reports are received.

            A description of the CDC influenza surveillance system, including methodology and detailed descriptions of each data component is available on the surveillance methods page.

            Additional information on the current and previous influenza seasons for each surveillance component are available on FluView Interactive.
            U.S. Virologic Surveillance

            Clinical Laboratories


            The results of tests performed by clinical laboratories nationwide are summarized below. Data from clinical laboratories (the percentage of specimens tested that are positive for influenza) are used to monitor whether influenza activity is increasing or decreasing.

            No. of specimens tested 40,698 3,612,434
            No. of positive specimens (%) 279 (0.7%) 135,450 (3.7%)
            Positive specimens by type
            Influenza A 263 (94.3%) 133,178 (98.3%)
            Influenza B 16 (5.7%) 2,272 (1.7%)

            View Chart Data | View Full Screen Public Health Laboratories


            The results of tests performed by public health laboratories nationwide are summarized below. Data from public health laboratories are used to monitor the proportion of circulating viruses that belong to each influenza subtype/lineage. Data from public health laboratories are used to monitor the proportion of circulating viruses that belong to each influenza subtype/lineage. Viruses known to be associated with recent live attenuated influenza vaccine (LAIV) receipt or found upon further testing to be a vaccine virus are not included, as they are not circulating influenza viruses.
            No. of specimens tested 10,145 1,093,878
            No. of positive specimens 38 25,990
            Positive specimens by type/subtype
            Influenza A 38 (100%) 25,839 (99.4%)
            (H1N1)pdm09 4 (14.8%) 56 (0.3%)
            H3N2 23 (85.2%) 20,464 (99.7%)
            H3N2v 0 4 (<0.1%)
            Subtyping not performed 11 5,315
            Influenza B 0 (0%) 151 (0.6%)
            Yamagata lineage 0 1 (2.3%)
            Victoria lineage 0 43 (97.7%)
            Lineage not performed 0 107



            View Chart Data | View Full Screen

            Additional virologic surveillance information for current and past seasons:
            Surveillance Methods | FluView Interactive: National, Regional, and State Data or Age Data
            Novel Influenza A Virus


            Two human infections with a novel influenza A virus were reported during week 36 (Michigan and Wisconsin). Both patients were infected with influenza A(H1N2) variant (A(H1N2)v) viruses.

            The Michigan Department of Health and Human Services reported one infection in a patient <18 years of age. The patient was not hospitalized and has recovered from their illness. An investigation by local public health officials found that the patient had attended an agricultural fair prior to their illness onset. Additional investigation identified one household contact who had respiratory illness. This contact attended the same agricultural fair and became ill at the same time as the patient. No person-to-person transmission of A(H1N2)v virus associated with this patient has been identified.

            The Wisconsin Department of Health reported one infection in a patient < 18 years of age. An investigation by local public health officials is ongoing.

            A total of seven human infections with variant novel influenza A viruses have been reported in the United States in 2022, including three H3N2v (West Virginia) and four H1N2v (Michigan, Ohio, Oregon, Wisconsin) viruses. When an influenza virus that normally circulates in swine (but not people) is detected in a person, it is called a “variant influenza virus.” Most human infections with variant influenza viruses occur following exposure to swine, but human-to-human transmission can occur. It is important to note that in most cases, variant influenza viruses have not shown the ability to spread easily and sustainably from person to person. Early identification and investigation of human infections with novel influenza A viruses are critical so that the risk of infection can be understood, and appropriate public health measures can be taken.

            Additional information on influenza in swine, variant influenza virus infection in humans, and guidance to interact safely with swine can be found at www.cdc.gov/flu/swineflu/index.htm.

            Additional information regarding human infections with novel influenza A viruses can be found at http://gis.cdc.gov/grasp/fluview/Novel_Influenza.html.
            Outpatient Respiratory Illness Surveillance


            The U.S. Outpatient Influenza-like Illness Surveillance Network (ILINet) monitors outpatient visits for influenza-like illness [ILI (fever plus cough or sore throat)], not laboratory-confirmed influenza, and will therefore capture respiratory illness visits due to infection with any pathogen that can present with similar symptoms, including influenza, SARS-CoV-2, and RSV. Due to the COVID-19 pandemic, health care-seeking behaviors have changed, and people may be accessing the health care system in alternative settings not captured as a part of ILINet or at a different point in their illness than they might have before the pandemic. Therefore, it is important to evaluate syndromic surveillance data, including that from ILINet, in the context of other sources of surveillance data to obtain a complete and accurate picture of influenza, SARS-CoV-2, and other respiratory virus activity. CDC is tracking the COVID-19 pandemic in a weekly publication called COVID Data Tracker Weekly Review. Information about other respiratory virus activity can be found on CDC’s National Respiratory and Enteric Virus Surveillance System (NREVSS) website.
            Outpatient Respiratory Illness Visits


            Nationwide during week 36, 1.9% of patient visits reported through ILINet were due to respiratory illness that included fever plus a cough or sore throat, also referred to as ILI. Multiple respiratory viruses are co-circulating, and the relative contribution of influenza virus infection to ILI varies by location.



            * Effective October 3, 2021 (week 40), the ILI definition (fever plus cough or sore throat) no longer includes “without a known cause other than influenza.”


            View Chart Data (current season only) | View Full ScreenOutpatient Respiratory Illness Visits by Age Group


            More than 70% of ILINet participants provide both the number of patient visits for respiratory illness and the total number of patient visits for the week broken out by age group. Data from this subset of providers are used to calculate the percentages of patient visits for respiratory illness by age group.

            During week 36, the percentage of visits for respiratory illness reported in ILINet was 7.8% among those 0-4 years, 3.1% among those 5-24 years, 1.1% among those 25-49 years, 0.8% among those 50-64 years, and 0.6% among those 65 years and older.



            * Effective October 3, 2021 (week 40), the ILI definition (fever plus cough or sore throat) no longer includes “without a known cause other than influenza.”

            View Chart Data | View Full Screen
            Outpatient Respiratory Illness Activity Map


            Data collected in ILINet are used to produce a measure of ILI activity* by state/jurisdiction and Core Based Statistical Areas (CBSA).
            Week 36

            (Week ending
            Sep. 10, 2022)
            Week 35

            (Week ending
            Sep. 3, 2022)
            Week 36

            (Week ending
            Sep. 10, 2022)
            Week 35

            (Week ending
            Sep. 3, 2022)
            Very High 0 0 4 5
            High 2 3 6 10
            Moderate 3 2 32 24
            Low 4 1 70 65
            Minimal 45 47 528 554
            Insufficient Data 1 2 289 271



            *Data collected in ILINet may disproportionally represent certain populations within a jurisdiction or CBSA, and therefore, may not accurately depict the full picture of influenza activity for the entire jurisdiction or CBSA. Differences in the data presented here by CDC and independently by some health departments likely represent differing levels of data completeness with data presented by the health department likely being the more complete.

            Additional information about medically attended visits for ILI for current and past seasons:
            Surveillance Methods | FluView Interactive: National, Regional, and State Data or ILI Activity Map
            Long-term Care Facility (LTCF) Surveillance


            LTCFs (e.g., nursing homes/skilled nursing, long-term care for the developmentally disabled, and assisted living facilities) from all 50 states and U.S. territories report data on influenza virus infections among residents through the National Healthcare Safety Network (NHSN) Long-term Care Facility Component. During week 36, 23 (0.2%) of 14,563 reporting LTCFs reported at least one influenza positive test among their residents.



            View Chart Data | View Full Screen

            Additional information about long-term care facility surveillance:
            Surveillance Methods | Additional Data
            Hospitalization Surveillance

            FluSurv-NET


            The Influenza Hospitalization Surveillance Network (FluSurv-NET) conducts population-based surveillance for laboratory-confirmed influenza-related hospitalizations in select counties in 14 states and represents approximately 9% of the U.S. population. FluSurv-NET hospitalization data are preliminary. Patients admitted for laboratory-confirmed influenza-related hospitalization after June 11, 2022, will not be included in FluSurv-NET for the 2021-2022 season. Data on patients admitted through June 11, 2022, will continue to be updated as additional information is received.

            Additional FluSurv-NET hospitalization surveillance information for current and past seasons and additional age groups:
            Surveillance Methods |FluView Interactive: Rates by Age, Sex, and Race/Ethnicity or Data on Patient Characteristics
            HHS Protect Hospitalization Surveillance


            Hospitals report to HHS Protect the number of patients admitted with laboratory-confirmed influenza. During week 36, 577 patients with laboratory-confirmed influenza were admitted to the hospital.



            View Chart Data | View Full Screen

            Additional HHS Protect hospitalization surveillance information:
            Surveillance Methods | Additional Data
            Mortality Surveillance

            National Center for Health Statistics (NCHS) Mortality Surveillance


            Based on NCHS mortality surveillance data available on September 15, 2022, 9.2% of the deaths that occurred during the week ending September 10, 2022 (week 36), were due to pneumonia, influenza, and/or COVID-19 (PIC). This percentage is above the epidemic threshold of 5.5% for this week. Among the 2,055 PIC deaths reported for this week, 1,052 had COVID-19 listed as an underlying or contributing cause of death on the death certificate, and five listed influenza, indicating that current PIC mortality is due primarily to COVID-19 and not influenza. The data presented are preliminary and may change as more data are received and processed.



            View Chart Data | View Full Screen

            Additional pneumonia, influenza and COVID-19 mortality surveillance information for current and past seasons:
            Surveillance Methods | FluView Interactive
            Influenza-Associated Pediatric Mortality


            One influenza-associated pediatric death occurring during the 2021-2022 season was reported to CDC during week 36. The death was associated with an influenza A(H3) virus and occurred during week 20 (the week ending May 21, 2022).

            A total of 35 influenza-associated pediatric deaths occurring during the 2021-2022 season have been reported to CDC.


            View Full Screen

            Additional pediatric mortality surveillance information for current and past seasons:
            Surveillance Methods | FluView Interactive


            Additional National and International Influenza Surveillance Information


            FluView Interactive: FluView includes enhanced web-based interactive applications that can provide dynamic visuals of the influenza data collected and analyzed by CDC. These FluView Interactive applications allow people to create customized, visual interpretations of influenza data, as well as make comparisons across flu seasons, regions, age groups and a variety of other demographics.

            National Institute for Occupational Safety and Health: Monthly surveillance data on the prevalence of health-related workplace absenteeism among full-time workers in the United States are available from NIOSH.

            U.S. State and local influenza surveillance: Select a jurisdiction below to access the latest local influenza information. World Health Organization:
            Additional influenza surveillance information from participating WHO member nations is available through
            FluNet and the Global Epidemiology Reports.

            WHO Collaborating Centers for Influenza:
            Australia, China, Japan, the United Kingdom, and the United States (CDC in Atlanta, Georgia)

            Europe:
            The most up-to-date influenza information from Europe is available from WHO/Europe and the European Centre for Disease Prevention and Control.

            Public Health Agency of Canada:
            The most up-to-date influenza information from Canada is available in Canada’s weekly FluWatch report.

            Public Health England:
            The most up-to-date influenza information from the United Kingdom is available from Public Health England.

            Any links provided to non-Federal organizations are provided solely as a service to our users. These links do not constitute an endorsement of these organizations or their programs by CDC or the Federal Government, and none should be inferred. CDC is not responsible for the content of the individual organization web pages found at these links.

            A description of the CDC influenza surveillance system, including methodology and detailed descriptions of each data component is available on the surveillance methods page.

            Learn more about the weekly influenza surveillance report (FluView) prepared by the Influenza Division.

            Comment


            • #66
              Weekly U.S. Influenza Surveillance Report


              Updated September 23, 2022

              2021-2022 Influenza Season for Week 37, ending September 17, 2022

              All data are preliminary and may change as more reports are received.

              A description of the CDC influenza surveillance system, including methodology and detailed descriptions of each data component is available on the surveillance methods page.

              Additional information on the current and previous influenza seasons for each surveillance component are available on FluView Interactive.
              U.S. Virologic Surveillance

              Clinical Laboratories


              The results of tests performed by clinical laboratories nationwide are summarized below. Data from clinical laboratories (the percentage of specimens tested that are positive for influenza) are used to monitor whether influenza activity is increasing or decreasing.

              No. of specimens tested 47,546 3,676,988
              No. of positive specimens (%) 378 (0.8%) 135,983 (3.7%)
              Positive specimens by type
              Influenza A 353 (93.4%) 133,676 (98.3%)
              Influenza B 25 (6.6%) 2,307 (1.7%)

              View Chart Data | View Full Screen Public Health Laboratories


              The results of tests performed by public health laboratories nationwide are summarized below. Data from public health laboratories are used to monitor the proportion of circulating viruses that belong to each influenza subtype/lineage. Data from public health laboratories are used to monitor the proportion of circulating viruses that belong to each influenza subtype/lineage. Viruses known to be associated with recent live attenuated influenza vaccine (LAIV) receipt or found upon further testing to be a vaccine virus are not included, as they are not circulating influenza viruses.
              No. of specimens tested 10,436 1,104,730
              No. of positive specimens 35 26,062
              Positive specimens by type/subtype
              Influenza A 31 (88.6%) 25,907 (99.4%)
              (H1N1)pdm09 2 (9.1%) 62 (0.3%)
              H3N2 20 (90.9%) 20,517 (99.7%)
              H3N2v 0 4 (<0.1%)
              Subtyping not performed 9 5,324
              Influenza B 4 (11.4%) 155 (0.6%)
              Yamagata lineage 0 1 (2.3%)
              Victoria lineage 0 43 (97.7%)
              Lineage not performed 4 111



              View Chart Data | View Full Screen

              Additional virologic surveillance information for current and past seasons:
              Surveillance Methods | FluView Interactive: National, Regional, and State Data or Age Data
              Novel Influenza A Virus


              A human infection with a novel influenza A virus was reported by the Georgia Department of Public Health. The patient was infected with an influenza A(H1N2) variant (A(H1N2)v) virus. The patient is <18 years of age, was not hospitalized, and has recovered from their illness. An investigation by local public health officials found that the patient had swine contact and had attended agricultural fairs prior to their illness onset. Additional investigation did not identify respiratory illness in any of the patient’s household contacts. No person-to-person transmission of A(H1N2)v virus associated with this patient has been identified.

              A total of eight human infections with variant novel influenza A viruses have been reported in the United States in 2022, including three H3N2v (West Virginia) and five H1N2v (Georgia, Michigan, Ohio, Oregon, Wisconsin) viruses. When an influenza virus that normally circulates in swine (but not people) is detected in a person, it is called a “variant influenza virus.” Most human infections with variant influenza viruses occur following exposure to swine, but human-to-human transmission can occur. It is important to note that in most cases, variant influenza viruses have not shown the ability to spread easily and sustainably from person to person.

              Early identification and investigation of human infections with novel influenza A viruses are critical so that the risk of infection can be understood, and appropriate public health measures can be taken.

              Additional information on influenza in swine, variant influenza virus infection in humans, and guidance to interact safely with swine can be found at www.cdc.gov/flu/swineflu/index.htm.

              Additional information regarding human infections with novel influenza A viruses can be found at http://gis.cdc.gov/grasp/fluview/Novel_Influenza.html.
              Outpatient Respiratory Illness Surveillance


              The U.S. Outpatient Influenza-like Illness Surveillance Network (ILINet) monitors outpatient visits for influenza-like illness [ILI (fever plus cough or sore throat)], not laboratory-confirmed influenza, and will therefore capture respiratory illness visits due to infection with any pathogen that can present with similar symptoms, including influenza, SARS-CoV-2, and RSV. Due to the COVID-19 pandemic, health care-seeking behaviors have changed, and people may be accessing the health care system in alternative settings not captured as a part of ILINet or at a different point in their illness than they might have before the pandemic. Therefore, it is important to evaluate syndromic surveillance data, including that from ILINet, in the context of other sources of surveillance data to obtain a complete and accurate picture of influenza, SARS-CoV-2, and other respiratory virus activity. CDC is tracking the COVID-19 pandemic in a weekly publication called COVID Data Tracker Weekly Review. Information about other respiratory virus activity can be found on CDC’s National Respiratory and Enteric Virus Surveillance System (NREVSS) website.
              Outpatient Respiratory Illness Visits


              Nationwide during week 37, 2.0% of patient visits reported through ILINet were due to respiratory illness that included fever plus a cough or sore throat, also referred to as ILI. Multiple respiratory viruses are co-circulating, and the relative contribution of influenza virus infection to ILI varies by location.



              * Effective October 3, 2021 (week 40), the ILI definition (fever plus cough or sore throat) no longer includes “without a known cause other than influenza.”


              View Chart Data (current season only) | View Full ScreenOutpatient Respiratory Illness Visits by Age Group


              More than 70% of ILINet participants provide both the number of patient visits for respiratory illness and the total number of patient visits for the week broken out by age group. Data from this subset of providers are used to calculate the percentages of patient visits for respiratory illness by age group.

              During week 37, the percentage of visits for respiratory illness reported in ILINet was 8.1% among those 0-4 years, 3.2% among those 5-24 years, 1.1% among those 25-49 years, 0.7% among those 50-64 years, and 0.5% among those 65 years and older.



              * Effective October 3, 2021 (week 40), the ILI definition (fever plus cough or sore throat) no longer includes “without a known cause other than influenza.”

              View Chart Data | View Full Screen
              Outpatient Respiratory Illness Activity Map


              Data collected in ILINet are used to produce a measure of ILI activity* by state/jurisdiction and Core Based Statistical Areas (CBSA).
              Week 37
              (Week ending
              Sep. 17, 2022)
              Week 36
              (Week ending
              Sep. 10, 2022)
              Week 37
              (Week ending
              Sep. 17, 2022)
              Week 36
              (Week ending
              Sep. 10, 2022)
              Very High 1 0 3 5
              High 1 2 9 6
              Moderate 3 3 24 32
              Low 3 4 71 72
              Minimal 47 46 546 545
              Insufficient Data 0 0 276 269



              *Data collected in ILINet may disproportionally represent certain populations within a jurisdiction or CBSA, and therefore, may not accurately depict the full picture of influenza activity for the entire jurisdiction or CBSA. Differences in the data presented here by CDC and independently by some health departments likely represent differing levels of data completeness with data presented by the health department likely being the more complete.

              Additional information about medically attended visits for ILI for current and past seasons:
              Surveillance Methods | FluView Interactive: National, Regional, and State Data or ILI Activity Map
              Long-term Care Facility (LTCF) Surveillance


              LTCFs (e.g., nursing homes/skilled nursing, long-term care for the developmentally disabled, and assisted living facilities) from all 50 states and U.S. territories report data on influenza virus infections among residents through the National Healthcare Safety Network (NHSN) Long-term Care Facility Component. During week 37, 32 (0.2%) of 14,515 reporting LTCFs reported at least one influenza positive test among their residents.



              View Chart Data | View Full Screen

              Additional information about long-term care facility surveillance:
              Surveillance Methods | Additional Data
              Hospitalization Surveillance

              FluSurv-NET


              The Influenza Hospitalization Surveillance Network (FluSurv-NET) conducts population-based surveillance for laboratory-confirmed influenza-related hospitalizations in select counties in 14 states and represents approximately 9% of the U.S. population. FluSurv-NET hospitalization data are preliminary. Patients admitted for laboratory-confirmed influenza-related hospitalization after June 11, 2022, will not be included in FluSurv-NET for the 2021-2022 season. Data on patients admitted through June 11, 2022, will continue to be updated as additional information is received.

              Additional FluSurv-NET hospitalization surveillance information for current and past seasons and additional age groups:
              Surveillance Methods |FluView Interactive: Rates by Age, Sex, and Race/Ethnicity or Data on Patient Characteristics
              HHS Protect Hospitalization Surveillance


              Hospitals report to HHS Protect the number of patients admitted with laboratory-confirmed influenza. During week 37, 637 patients with laboratory-confirmed influenza were admitted to the hospital.



              View Chart Data | View Full Screen

              Additional HHS Protect hospitalization surveillance information:
              Surveillance Methods | Additional Data
              Mortality Surveillance

              National Center for Health Statistics (NCHS) Mortality Surveillance


              Based on NCHS mortality surveillance data available on September 22, 2022, 9.2% of the deaths that occurred during the week ending September 17, 2022 (week 37), were due to pneumonia, influenza, and/or COVID-19 (PIC). This percentage is above the epidemic threshold of 5.6% for this week. Among the 2,058 PIC deaths reported for this week, 1,055 had COVID-19 listed as an underlying or contributing cause of death on the death certificate, and four listed influenza, indicating that current PIC mortality is due primarily to COVID-19 and not influenza. The data presented are preliminary and may change as more data are received and processed.



              View Chart Data | View Full Screen

              Additional pneumonia, influenza and COVID-19 mortality surveillance information for current and past seasons:
              Surveillance Methods | FluView Interactive
              Influenza-Associated Pediatric Mortality


              Two influenza-associated pediatric deaths occurring during the 2021-2022 season were reported to CDC during week 37. One death was associated with an influenza B virus with no lineage determined and occurred during week 15 (the week ending April 16, 2022). The other death was associated with an influenza A(H3) virus and occurred during week 21 (the week ending May 28, 2022).

              A total of 37 influenza-associated pediatric deaths occurring during the 2021-2022 season have been reported to CDC.


              View Full Screen

              Additional pediatric mortality surveillance information for current and past seasons:
              Surveillance Methods | FluView Interactive


              Additional National and International Influenza Surveillance Information


              FluView Interactive: FluView includes enhanced web-based interactive applications that can provide dynamic visuals of the influenza data collected and analyzed by CDC. These FluView Interactive applications allow people to create customized, visual interpretations of influenza data, as well as make comparisons across flu seasons, regions, age groups and a variety of other demographics.

              National Institute for Occupational Safety and Health: Monthly surveillance data on the prevalence of health-related workplace absenteeism among full-time workers in the United States are available from NIOSH.

              U.S. State and local influenza surveillance: Select a jurisdiction below to access the latest local influenza information. World Health Organization:
              Additional influenza surveillance information from participating WHO member nations is available through
              FluNet and the Global Epidemiology Reports.

              WHO Collaborating Centers for Influenza:
              Australia, China, Japan, the United Kingdom, and the United States (CDC in Atlanta, Georgia)

              Europe:
              The most up-to-date influenza information from Europe is available from WHO/Europe and the European Centre for Disease Prevention and Control.

              Public Health Agency of Canada:
              The most up-to-date influenza information from Canada is available in Canada’s weekly FluWatch report.

              Public Health England:
              The most up-to-date influenza information from the United Kingdom is available from Public Health England.

              Any links provided to non-Federal organizations are provided solely as a service to our users. These links do not constitute an endorsement of these organizations or their programs by CDC or the Federal Government, and none should be inferred. CDC is not responsible for the content of the individual organization web pages found at these links.

              A description of the CDC influenza surveillance system, including methodology and detailed descriptions of each data component is available on the surveillance methods page.

              Learn more about the weekly influenza surveillance report (FluView) prepared by the Influenza Division.

              Comment


              • #67

                Weekly U.S. Influenza Surveillance Report

                Print
                Updated September 30, 2022

                2021-2022 Influenza Season for Week 38, ending September 24, 2022

                All data are preliminary and may change as more reports are received.

                A description of the CDC influenza surveillance system, including methodology and detailed descriptions of each data component is available on the surveillance methods page.

                Additional information on the current and previous influenza seasons for each surveillance component are available on FluView Interactive.
                U.S. Virologic Surveillance

                Clinical Laboratories


                The results of tests performed by clinical laboratories nationwide are summarized below. Data from clinical laboratories (the percentage of specimens tested that are positive for influenza) are used to monitor whether influenza activity is increasing or decreasing.

                No. of specimens tested 50,292 3,743,239
                No. of positive specimens (%) 677 (1.3%) 136,829 (3.7%)
                Positive specimens by type
                Influenza A 628 (92.8%) 134,464 (98.3%)
                Influenza B 49 (7.2%) 2,365 (1.7%)

                View Chart Data | View Full Screen Public Health Laboratories


                The results of tests performed by public health laboratories nationwide are summarized below. Data from public health laboratories are used to monitor the proportion of circulating viruses that belong to each influenza subtype/lineage. Data from public health laboratories are used to monitor the proportion of circulating viruses that belong to each influenza subtype/lineage. Viruses known to be associated with recent live attenuated influenza vaccine (LAIV) receipt or found upon further testing to be a vaccine virus are not included, as they are not circulating influenza viruses.
                No. of specimens tested 9,907 1,115,302
                No. of positive specimens 52 26,181
                Positive specimens by type/subtype
                Influenza A 47 (90.4%) 26,020 (99.4%)
                (H1N1)pdm09 12 (36.4%) 75 (0.4%)
                H3N2 21 (63.6%) 20,591 (99.6%)
                H3N2v 0 4 (<0.1%)
                Subtyping not performed 14 5,350
                Influenza B 5 (9.6%) 161 (0.6%)
                Yamagata lineage 0 1 (2.3%)
                Victoria lineage 0 43 (97.7%)
                Lineage not performed 5 117



                View Chart Data | View Full Screen

                Additional virologic surveillance information for current and past seasons:
                Surveillance Methods | FluView Interactive: National, Regional, and State Data or Age Data
                Outpatient Respiratory Illness Surveillance


                The U.S. Outpatient Influenza-like Illness Surveillance Network (ILINet) monitors outpatient visits for influenza-like illness [ILI (fever plus cough or sore throat)], not laboratory-confirmed influenza, and will therefore capture respiratory illness visits due to infection with any pathogen that can present with similar symptoms, including influenza, SARS-CoV-2, and RSV. Due to the COVID-19 pandemic, health care-seeking behaviors have changed, and people may be accessing the health care system in alternative settings not captured as a part of ILINet or at a different point in their illness than they might have before the pandemic. Therefore, it is important to evaluate syndromic surveillance data, including that from ILINet, in the context of other sources of surveillance data to obtain a complete and accurate picture of influenza, SARS-CoV-2, and other respiratory virus activity. CDC is tracking the COVID-19 pandemic in a weekly publication called COVID Data Tracker Weekly Review. Information about other respiratory virus activity can be found on CDC’s National Respiratory and Enteric Virus Surveillance System (NREVSS) website.
                Outpatient Respiratory Illness Visits


                Nationwide during week 38, 2.2% of patient visits reported through ILINet were due to respiratory illness that included fever plus a cough or sore throat, also referred to as ILI. Multiple respiratory viruses are co-circulating, and the relative contribution of influenza virus infection to ILI varies by location.



                * Effective October 3, 2021 (week 40), the ILI definition (fever plus cough or sore throat) no longer includes “without a known cause other than influenza.”


                View Chart Data (current season only) | View Full ScreenOutpatient Respiratory Illness Visits by Age Group


                More than 70% of ILINet participants provide both the number of patient visits for respiratory illness and the total number of patient visits for the week broken out by age group. Data from this subset of providers are used to calculate the percentages of patient visits for respiratory illness by age group.

                During week 38, the percentage of visits for respiratory illness reported in ILINet was 9.0% among those 0-4 years, 3.5% among those 5-24 years, 1.1% among those 25-49 years, 0.7% among those 50-64 years, and 0.6% among those 65 years and older.



                * Effective October 3, 2021 (week 40), the ILI definition (fever plus cough or sore throat) no longer includes “without a known cause other than influenza.”

                View Chart Data | View Full Screen
                Outpatient Respiratory Illness Activity Map


                Data collected in ILINet are used to produce a measure of ILI activity* by state/jurisdiction and Core Based Statistical Areas (CBSA).
                Week 38
                (Week ending
                Sep. 24, 2022)
                Week 37
                (Week ending
                Sep. 17, 2022)
                Week 38
                (Week ending
                Sep. 24, 2022)
                Week 37
                (Week ending
                Sep. 17, 2022)
                Very High 0 0 4 3
                High 3 2 13 8
                Moderate 2 2 29 24
                Low 9 5 85 73
                Minimal 40 46 520 555
                Insufficient Data 1 0 278 266



                *Data collected in ILINet may disproportionally represent certain populations within a jurisdiction or CBSA, and therefore, may not accurately depict the full picture of influenza activity for the entire jurisdiction or CBSA. Differences in the data presented here by CDC and independently by some health departments likely represent differing levels of data completeness with data presented by the health department likely being the more complete.

                Additional information about medically attended visits for ILI for current and past seasons:
                Surveillance Methods | FluView Interactive: National, Regional, and State Data or ILI Activity Map
                Long-term Care Facility (LTCF) Surveillance


                LTCFs (e.g., nursing homes/skilled nursing, long-term care for the developmentally disabled, and assisted living facilities) from all 50 states and U.S. territories report data on influenza virus infections among residents through the National Healthcare Safety Network (NHSN) Long-term Care Facility Component. During week 38, 31 (0.2%) of 14,528 reporting LTCFs reported at least one influenza positive test among their residents.



                View Chart Data | View Full Screen

                Additional information about long-term care facility surveillance:
                Surveillance Methods | Additional Data
                Hospitalization Surveillance

                FluSurv-NET


                The Influenza Hospitalization Surveillance Network (FluSurv-NET) conducts population-based surveillance for laboratory-confirmed influenza-related hospitalizations in select counties in 14 states and represents approximately 9% of the U.S. population. FluSurv-NET hospitalization data are preliminary. Patients admitted for laboratory-confirmed influenza-related hospitalization after June 11, 2022, will not be included in FluSurv-NET for the 2021-2022 season. Data on patients admitted through June 11, 2022, will continue to be updated as additional information is received.

                Additional FluSurv-NET hospitalization surveillance information for current and past seasons and additional age groups:
                Surveillance Methods |FluView Interactive: Rates by Age, Sex, and Race/Ethnicity or Data on Patient Characteristics
                HHS Protect Hospitalization Surveillance


                Hospitals report to HHS Protect the number of patients admitted with laboratory-confirmed influenza. During week 38, 739 patients with laboratory-confirmed influenza were admitted to the hospital.



                View Chart Data | View Full Screen

                Additional HHS Protect hospitalization surveillance information:
                Surveillance Methods | Additional Data
                Mortality Surveillance

                National Center for Health Statistics (NCHS) Mortality Surveillance


                Based on NCHS mortality surveillance data available on September 29, 2022, 8.7% of the deaths that occurred during the week ending September 24, 2022 (week 38), were due to pneumonia, influenza, and/or COVID-19 (PIC). This percentage is above the epidemic threshold of 5.6% for this week. Among the 2,035 PIC deaths reported for this week, 1,014 had COVID-19 listed as an underlying or contributing cause of death on the death certificate, and six listed influenza, indicating that current PIC mortality is due primarily to COVID-19 and not influenza. The data presented are preliminary and may change as more data are received and processed.



                View Chart Data | View Full Screen

                Additional pneumonia, influenza and COVID-19 mortality surveillance information for current and past seasons:
                Surveillance Methods | FluView Interactive
                Influenza-Associated Pediatric Mortality


                Two influenza-associated pediatric deaths occurring in weeks 30 (the week ending July 30, 2022) and 33 (the week ending August 20, 2022) of the 2021-2022 season were reported to CDC during week 38. Both deaths were associated with influenza A viruses for which no subtyping was performed.

                A total of 39 influenza-associated pediatric deaths occurring during the 2021-2022 season have been reported to CDC.


                View Full Screen

                Additional pediatric mortality surveillance information for current and past seasons:
                Surveillance Methods | FluView Interactive


                Additional National and International Influenza Surveillance Information


                FluView Interactive: FluView includes enhanced web-based interactive applications that can provide dynamic visuals of the influenza data collected and analyzed by CDC. These FluView Interactive applications allow people to create customized, visual interpretations of influenza data, as well as make comparisons across flu seasons, regions, age groups and a variety of other demographics.

                National Institute for Occupational Safety and Health: Monthly surveillance data on the prevalence of health-related workplace absenteeism among full-time workers in the United States are available from NIOSH.

                U.S. State and local influenza surveillance: Select a jurisdiction below to access the latest local influenza information. World Health Organization:
                Additional influenza surveillance information from participating WHO member nations is available through
                FluNet and the Global Epidemiology Reports.

                WHO Collaborating Centers for Influenza:
                Australia, China, Japan, the United Kingdom, and the United States (CDC in Atlanta, Georgia)

                Europe:
                The most up-to-date influenza information from Europe is available from WHO/Europe and the European Centre for Disease Prevention and Control.

                Public Health Agency of Canada:
                The most up-to-date influenza information from Canada is available in Canada’s weekly FluWatch report.

                Public Health England:
                The most up-to-date influenza information from the United Kingdom is available from Public Health England.

                Any links provided to non-Federal organizations are provided solely as a service to our users. These links do not constitute an endorsement of these organizations or their programs by CDC or the Federal Government, and none should be inferred. CDC is not responsible for the content of the individual organization web pages found at these links.

                A description of the CDC influenza surveillance system, including methodology and detailed descriptions of each data component is available on the surveillance methods page.

                Learn more about the weekly influenza surveillance report (FluView) prepared by the Influenza Division.

                Comment

                Working...
                X